|Series B, 2/2007 |
Novartis Venture Fund
|Partial Close, 8/2009 ||$11.7M|
|Debt, 11/2011 ||$235k|
Trellis Bioscience develops a technology platform for cellular informatics. The companyâ€™s technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.